Chargement des cours...
Prévisions
| Acheter |
1 |
| Conserver |
0 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Biofrontera sells US license for Xepi to Pelthos Therapeutics for up to $10 million
Biofrontera has sold the US rights to the Xepi cream to Pelthos Therapeutics. The agreement foresees $3 million at signing, $1 million upon commercial availability and up to $6 million in revenue-dependent milestones (payments tied to $10 million and $15 million in annual sales in the USA, Puerto Rico and the US Virgin Islands). The company stresses the transaction strengthens the balance sheet and should secure financing until profitability; proceeds are to support growth of the photodynamic therapy platform and regulatory expansions for Ameluz. Biofrontera recently had more liquid assets than debt but a rapid cash burn; it also recently took over the US rights to Ameluz and RhodoLED and agreed an earn-out model. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | mars 2026 | |
|---|---|---|
| Chiffre d'affaires | 3,71 M | - |
| Bénéfice brut | 3,01 M | - |
| Bénéfice net | 2,2 M | - |
| EBITDA | 106 k | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 113,66 M € |
Nombre d'actions | 44,57 M |
Plus haut/bas sur 52 semaines | 2,55 € - 2,55 € |
| Dividendes | Non |
Bêta | -0,24 |
Ratio P/E | -2,68 |
Ratio PEG | -0,02 |
Ratio P/B | 3,49 |
Ratio P/S | 0,45 |
Profil de l'entreprise
| Nom | Biofrontera Aktie |
| PDG | Hermann Lübbert |
| Employés | 88 |
Découvrir des actifs
Les actionnaires de Biofrontera Aktie investissent également dans les actifs suivants
